“The only way to discover the limits of the possible is to go beyond them into the impossible.”

–Arthur C. Clarke

Leading the future
of cancer diagnosis

Stewart Bartlett CEO Ferronova

Stewart Bartlett, CEO

Stewart was a co-founder of medical device company Signostics. From 2005-2017 he was COO of Signostics, managing product development, manufacturing, quality, regulatory, customer service, OEM partnerships, and at various times sales and marketing. Prior to Signostics, he held several management positions at Lake Technology Ltd, including managing director of a subsidiary responsible for licensing Lake’s technology. He has worked in a variety of management, engineering and sales and marketing roles in Australia, the United States, and Europe, and holds a Bachelor of Electrical Engineering with Honors from Curtin University and a Master of Business Administration from The Australian Graduate School of Management.


Dr Anil Shetty, CMO

Dr Shetty is the Chief Medical Officer and manages the US office in Houston, Texas. Dr Shetty was the Director of Clinical Operations at Visualase, and a key member of the executive team which led the Houston-based medical startup to a $110 million Medtronic acquisition. He has also led development of products for epilepsy, spinal tumors, radiation necrosis and prostate cancer, and developed a network of clinics offering MRI guided biopsy and focal therapy for prostate cancer. He has a fellowship from MD Anderson Cancer Center and a Biomedical Engineering degree from Texas A&M. He has co-authored 30+peer-reviewed publications in oncology, radiology, neurology and neurosurgery.

The board

Dr John Parker, Chair

Dr John Parker

From 2013 to 2021, John was the founder, CEO, and a director of closed-loop feedback spinal stimulation company Saluda Medical, and remains as the Chief Scientific Officer. Prior to Saluda, John founded the Implant Systems team at NICTA, where the core Saluda technology was developed.

Dr. Parker has nearly 30 years of experience in active implantable medical devices, including 13 years at Cochlear Limited, where he served in the role of Chief Technology Officer / executive member of the board of directors.

John has a PhD in physical chemistry from ANU and has worked in both Australian and international universities, authored numerous scientific publications and patents, is an ATSE fellow, Harvard business School (PMD) graduate, Docent at the Royal Institute of technology in Stockholm Sweden, ATSE Clunies Ross Medallist (2010), Adjunct Professor UNSW School of Biomedical Engineering, and expert advisor to the NSW Medical Device Fund.

Tamara is Managing Director of ImpactXHealth,

Tamara Mills
Independent Director

Tamara is Managing Director of ImpactXHealth, an organisation supporting the growth and facilitating strategic investments companies involved in the development of breakthrough medical and healthcare technologies.

Tamara has extensive experience in global regulatory affairs, health economics, product development, market access and commercialization of innovative medical technologies in the diagnostic imaging sector, across the United States, Japan, Brazil, Europe and Australia. Tamara built and led the Cardiovascular Diagnostics Business for Jubilant Life Sciences, where she successfully led complex drug-device diagnostic imaging products through regulatory approval and commercialization.

Tamara most recently held the position of Chair of the Health Policy, Regulatory and Reimbursement committee for the North American Radiopharmaceutical Industry organization CORAR in addition to holding a key leadership role for the Medical Imaging Technology Alliance. Tamara has an MBA, Masters in Health Economics, a Degree in Applied Nuclear Physics and a qualification in New Ventures Leadership from the Massachusetts Institute of Technology.

David Rohrsheim

David Rohrsheim
Independent Director

David is a Venture Partner for Artesian and manager of the South Australian Venture Capital Fund. David was previously the General Manager, Uber (Australia & NZ) and opened Uber’s operations in Australia in 2012. He previously worked as an Analyst at US VC firm Draper Fisher Jurvetson from 2008 to 2010. He was involved in sourcing companies, structuring transactions and serving as a Board observer for a range of software and hardware companies. Prior to joining DFJ, David was a Senior Associate Consultant at Bain & Company working in Sydney and London. He received an MBA from Stanford University after an B.Eng. (IT&T, First Class Honours) and B.Fin. from Adelaide University. He is a graduate from the AICD.

Dr John Parker, Chair

Paul Butler
Uniseed Director

Paul Butler is Uniseed’s Investment Manager based at UQ. Paul is an experienced General Manager who has led and developed teams in a technology domain across the communications, medical and mining industries. Prior to Uniseed Paul was CEO at Serene Medical, CEO at SmartCap Technologies, Executive General Manager Products at GroundProbe and CEO of ASX listed USCOM. Paul was previously an Investment Manager at Uniseed in Sydney and also started his own consulting business, CEO Alliance, to support technology companies as they navigate their way to commercialisation having market experience in Australia, Europe and the USA.

Paul is a Graduate of the Australian Institute of Company Directors and with qualifications in Electrical Engineering and a Bachelor of Economics, he has been able to develop and bring new products to market. Through various roles Paul has had liaison with customers via direct and indirect sales, government health systems, contract manufacturers (domestic, Asian and USA), third party logistics providers, distribution channels and financial auditors.

The commercial team behind our vision

Shanrah Randall - Ferronova

Shanrah Randall, Global Marketing Director


Joe El-Aklouk,
Senior Product Manager


Leticia Cubero Dominguez,
QA & Regulatory Manager

Melanie Nelson

Dr Melanie Nelson,
R&D Manager

Aidan Cousins Ferronova

Dr Aidan Cousins,
Senior Research Physicist